Tyr530
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr530  -  Src (human)

Site Information
FTstEPQyQPGENL_   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448235
Available spectra:  2 CST
Associated spectra:  10 CST

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 11 ) , [32P] bio-synthetic labeling ( 972 , 975 , 977 ) , immunoprecipitation ( 7 , 9 , 11 , 13 , 16 , 18 , 19 , 25 , 28 , 39 , 73 , 162 , 164 , 974 ) , mass spectrometry ( 9 , 11 , 18 , 20 , 26 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 38 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 74 , 75 , 76 , 78 , 79 , 80 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 154 , 155 , 156 , 157 , 159 , 160 , 161 , 163 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 348 , 349 , 350 , 351 , 352 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 371 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 420 , 421 , 422 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 , 436 , 437 , 438 , 439 , 440 , 441 , 442 , 443 , 444 , 445 , 446 , 447 , 448 , 449 , 450 , 451 , 452 , 453 , 454 , 455 , 456 , 457 , 458 , 459 , 460 , 461 , 462 , 463 , 464 , 465 , 466 , 467 , 468 , 469 , 470 , 471 , 472 , 473 , 474 , 475 , 476 , 477 , 478 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 486 , 487 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 495 , 496 , 497 , 498 , 499 , 500 , 501 , 502 , 503 , 504 , 505 , 506 , 507 , 508 , 509 , 511 , 512 , 513 , 514 , 515 , 516 , 517 , 518 , 519 , 520 , 521 , 522 , 523 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 537 , 538 , 539 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 553 , 554 , 555 , 556 , 557 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 565 , 566 , 567 , 568 , 569 , 570 , 571 , 572 , 573 , 574 , 575 , 576 , 577 , 578 , 579 , 580 , 581 , 582 , 583 , 584 , 585 , 586 , 587 , 588 , 589 , 590 , 591 , 592 , 593 , 594 , 595 , 596 , 597 , 598 , 599 , 600 , 601 , 602 , 603 , 604 , 605 , 606 , 607 , 608 , 609 , 610 , 611 , 612 , 613 , 614 , 615 , 616 , 617 , 618 , 619 , 620 , 621 , 622 , 623 , 624 , 625 , 626 , 627 , 629 , 630 , 631 , 632 , 633 , 634 , 635 , 636 , 637 , 638 , 639 , 640 , 641 , 642 , 643 , 644 , 645 , 646 , 647 , 649 , 650 , 651 , 652 , 653 , 654 , 655 , 656 , 657 , 658 , 659 , 660 , 661 , 662 , 663 , 664 , 665 , 666 , 667 , 668 , 669 , 670 , 671 , 672 , 673 , 674 , 676 , 677 , 678 , 679 , 680 , 681 , 682 , 683 , 684 , 685 , 686 , 687 , 688 , 689 , 690 , 691 , 692 , 693 , 694 , 695 , 696 , 697 , 698 , 699 , 700 , 701 , 702 , 704 , 705 , 706 , 707 , 708 , 709 , 710 , 711 , 712 , 713 , 714 , 715 , 716 , 717 , 718 , 719 , 720 , 721 , 722 , 723 , 724 , 725 , 726 , 727 , 728 , 729 , 730 , 731 , 732 , 733 , 734 , 735 , 736 , 737 , 738 , 739 , 740 , 741 , 742 , 743 , 744 , 745 , 746 , 747 , 748 , 749 , 750 , 751 , 752 , 753 , 754 , 755 , 756 , 757 , 758 , 759 , 760 , 762 , 763 , 764 , 765 , 766 , 767 , 769 , 770 , 771 , 772 , 773 , 774 , 775 , 776 , 778 , 779 , 780 , 781 , 782 , 783 , 784 , 785 , 786 , 787 , 788 , 789 , 790 , 791 , 792 , 793 , 794 , 795 , 796 , 797 , 798 , 799 , 800 , 801 , 802 , 803 , 804 , 805 , 806 , 807 , 808 , 809 , 810 , 811 , 812 , 813 , 814 , 815 , 816 , 817 , 818 , 819 , 820 , 821 , 823 , 824 , 825 , 826 , 827 , 828 , 829 , 830 , 831 , 832 , 833 , 834 , 835 , 836 , 837 , 838 , 839 , 840 , 841 , 842 , 844 , 845 , 847 , 848 , 849 , 850 , 851 , 852 , 853 , 854 , 855 , 856 , 857 , 858 , 859 , 860 , 861 , 862 , 863 , 864 , 865 , 866 , 867 , 869 , 870 , 871 , 872 , 873 , 874 , 875 , 876 , 877 , 878 , 879 , 880 , 882 , 883 , 884 , 885 , 886 , 887 , 890 , 891 , 892 , 893 , 894 , 895 , 896 , 897 , 898 , 899 , 900 , 901 , 902 , 904 , 906 , 907 , 909 , 910 , 911 , 913 , 914 , 916 , 917 , 918 , 919 , 920 , 921 , 922 , 923 , 924 , 925 , 927 , 928 , 929 , 930 , 931 , 932 , 933 , 934 , 936 , 937 , 938 , 939 , 940 , 941 , 942 , 943 , 944 , 945 , 947 , 948 , 949 , 950 , 951 , 952 , 953 , 954 , 955 , 957 , 961 ) , mass spectrometry (in vitro) ( 935 ) , microscopy-colocalization with upstream kinase ( 162 ) , mutation of modification site ( 4 , 7 , 9 , 23 , 24 , 37 , 39 , 41 , 73 , 117 , 958 , 965 , 967 , 969 , 973 , 974 ) , phospho-antibody ( 3 , 4 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 21 , 22 , 24 , 25 , 27 , 28 , 40 , 42 , 43 , 44 , 71 , 72 , 73 , 77 , 117 , 141 , 153 , 158 , 162 , 164 , 510 , 536 , 628 , 648 , 675 , 703 , 761 , 768 , 777 , 822 , 843 , 881 , 888 , 889 , 903 , 905 , 908 , 912 , 915 , 926 , 946 , 956 , 959 , 960 , 962 , 963 , 964 , 965 , 966 , 968 , 969 , 970 , 971 , 972 , 973 , 974 ) , phosphoamino acid analysis ( 972 ) , phosphopeptide mapping ( 975 , 977 ) , western blotting ( 3 , 4 , 7 , 8 , 9 , 10 , 11 , 13 , 15 , 16 , 17 , 18 , 19 , 21 , 22 , 24 , 25 , 27 , 28 , 39 , 40 , 42 , 43 , 44 , 71 , 72 , 73 , 77 , 117 , 141 , 153 , 158 , 162 , 164 , 510 , 536 , 628 , 648 , 675 , 703 , 761 , 768 , 777 , 822 , 843 , 881 , 888 , 889 , 903 , 908 , 912 , 926 , 959 , 960 , 962 , 963 , 964 , 969 , 971 , 973 , 974 )
Disease tissue studied:
atrial fibrillation ( 685 , 686 , 687 ) , adenoid cystic carcinoma ( 549 , 551 ) , bile-duct cancer ( 58 , 59 , 497 , 498 ) , bladder cancer ( 239 , 240 , 241 , 842 , 843 ) , bladder cancer, surrounding tissue ( 230 , 237 , 238 ) , bone cancer ( 14 , 739 , 740 , 741 , 766 , 767 ) , Ewing's sarcoma ( 767 ) , osteosarcoma ( 739 , 740 , 741 , 766 ) , brain cancer ( 72 , 703 , 878 , 898 , 899 , 900 ) , glioblastoma ( 878 , 898 , 899 , 900 ) , glioblastoma multiforme ( 878 , 899 , 900 ) , glioma ( 878 , 898 , 899 , 900 ) , medulloblastoma ( 72 ) , breast cancer ( 4 , 9 , 13 , 14 , 18 , 24 , 35 , 40 , 117 , 162 , 224 , 225 , 226 , 227 , 231 , 232 , 233 , 234 , 235 , 236 , 345 , 346 , 648 , 667 , 668 , 669 , 670 , 671 , 672 , 673 , 676 , 677 , 689 , 728 , 729 , 771 , 774 , 837 , 838 , 844 , 848 , 849 , 857 , 870 , 906 , 908 , 957 , 961 , 963 ) , breast adenocarcinoma ( 117 , 849 , 957 , 961 ) , breast cancer, surrounding tissue ( 224 , 226 , 231 , 232 , 236 , 689 ) , breast cancer, triple negative ( 13 , 40 , 117 ) , colorectal cancer ( 3 , 11 , 19 , 42 , 67 , 68 , 69 , 87 , 88 , 93 , 94 , 448 , 451 , 452 , 459 , 461 , 644 , 646 , 647 , 648 , 653 , 654 , 657 , 761 , 765 , 904 , 916 , 917 , 953 ) , colorectal carcinoma ( 3 , 11 , 19 , 42 , 67 , 68 , 69 , 87 , 88 , 93 , 94 , 648 , 761 , 904 , 916 , 917 , 953 ) , colorectal cancer, surrounding tissue ( 450 , 453 , 454 , 460 , 462 , 485 , 590 , 610 , 645 , 656 ) , esophageal cancer ( 57 , 171 , 353 , 355 , 356 , 358 , 359 , 361 , 365 , 370 , 371 , 375 , 376 , 379 , 380 , 381 , 382 , 386 , 387 , 388 , 390 , 394 , 395 , 399 , 402 , 404 , 406 , 407 , 409 , 411 , 412 , 413 , 416 , 418 , 419 , 424 , 425 , 432 , 433 , 434 , 435 , 437 , 438 , 441 , 858 , 859 , 860 , 861 ) , esophageal carcinoma ( 171 , 858 , 859 , 861 ) , esophageal cancer, surrounding tissue ( 352 , 354 , 357 , 360 , 362 , 363 , 364 , 366 , 367 , 368 , 369 , 372 , 373 , 374 , 377 , 378 , 383 , 384 , 385 , 389 , 391 , 392 , 393 , 396 , 397 , 398 , 400 , 401 , 403 , 405 , 408 , 410 , 414 , 415 , 417 , 420 , 421 , 422 , 423 , 426 , 427 , 428 , 429 , 430 , 431 , 436 , 439 , 440 , 443 , 444 ) , liposarcoma ( 46 ) , gastric cancer ( 54 , 55 , 56 , 74 , 75 , 76 , 77 , 95 , 96 , 166 , 167 , 168 , 169 , 191 , 193 , 200 , 202 , 203 , 208 , 209 , 211 , 212 , 213 , 455 , 543 , 561 , 563 , 564 , 566 , 567 , 569 , 573 , 575 , 577 , 579 , 581 , 584 , 586 , 587 , 589 , 594 , 595 , 597 , 599 , 601 , 603 , 605 , 678 , 680 , 681 , 696 , 702 , 706 , 707 , 708 , 709 , 710 , 712 , 714 , 718 , 719 , 720 , 721 , 722 , 730 , 781 , 782 , 799 , 845 , 875 , 876 , 877 , 879 ) , gastric carcinoma ( 74 , 75 , 76 , 77 , 95 , 96 , 166 , 167 , 168 , 169 , 191 , 193 , 200 , 455 , 561 , 563 , 564 , 566 , 567 , 569 , 573 , 575 , 577 , 579 , 581 , 584 , 586 , 587 , 589 , 678 , 680 , 681 , 702 , 730 , 781 , 782 , 799 , 876 ) , gastric carcinoma, surrounding tissue ( 201 , 204 , 205 , 206 , 207 , 210 , 214 , 560 , 562 , 565 , 568 , 570 , 571 , 572 , 574 , 576 , 578 , 580 , 582 , 583 , 585 , 588 , 593 , 596 , 598 , 602 , 604 , 606 , 679 , 694 , 695 , 700 , 701 , 711 , 713 , 715 ) , kidney cancer ( 243 , 258 , 259 , 260 , 280 ) , kidney cancer, surrounding tissue ( 279 , 281 ) , laryngeal cancer ( 666 , 751 , 752 , 753 , 754 , 770 , 776 ) , leukemia ( 70 , 134 , 135 , 136 , 137 , 138 , 139 , 179 , 192 , 196 , 219 , 228 , 229 , 250 , 251 , 252 , 325 , 342 , 344 , 490 , 491 , 665 , 682 , 763 , 769 , 787 , 788 , 790 , 791 , 792 , 793 , 794 , 795 , 801 , 802 , 803 , 804 , 805 , 806 , 807 , 808 , 809 , 865 , 886 , 887 , 890 , 891 , 892 , 902 , 907 , 921 , 936 , 937 , 938 ) , acute myelogenous leukemia ( 791 , 792 , 793 , 794 , 795 , 801 , 802 , 803 , 804 , 806 , 865 , 886 , 887 , 890 , 891 , 892 , 902 , 907 , 937 , 938 ) , chronic lymphocytic leukemia ( 921 , 936 ) , chronic myelogenous leukemia ( 70 , 134 , 135 , 136 , 137 , 138 , 139 , 179 , 192 , 196 , 219 , 228 , 229 , 250 , 251 , 252 , 325 , 342 , 344 , 490 , 491 , 665 , 682 , 769 , 787 , 788 , 790 , 805 , 807 , 808 , 809 ) , liver cancer ( 140 , 245 , 246 , 284 , 286 , 288 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 304 , 305 , 306 , 308 , 309 , 312 , 313 , 315 , 316 , 318 , 321 , 322 , 449 , 469 , 470 , 472 , 525 , 528 , 529 , 530 , 611 , 612 , 633 , 636 , 637 , 638 , 717 ) , cholangiocellular carcinoma ( 140 , 292 , 304 , 316 , 469 , 470 , 638 ) , cholangiocellular carcinoma, surrounding tissue ( 302 , 484 , 642 , 716 ) , hepatocellular carcinoma ( 23 , 284 , 286 , 288 , 291 , 293 , 294 , 295 , 298 , 299 , 300 , 305 , 306 , 308 , 309 , 312 , 315 , 318 , 321 , 322 , 611 , 633 , 636 , 637 , 717 ) , hepatocellular carcinoma, surrounding tissue ( 285 , 287 , 301 , 303 , 307 , 310 , 314 , 471 , 634 ) , liver cancer, surrounding tissue ( 242 , 244 , 311 ) , lung cancer ( 12 , 16 , 29 , 30 , 31 , 32 , 33 , 34 , 36 , 45 , 49 , 50 , 51 , 52 , 53 , 71 , 83 , 84 , 85 , 86 , 89 , 90 , 91 , 92 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 113 , 131 , 156 , 170 , 174 , 176 , 184 , 185 , 186 , 187 , 189 , 200 , 262 , 264 , 266 , 268 , 278 , 323 , 324 , 326 , 327 , 328 , 329 , 331 , 332 , 334 , 335 , 336 , 338 , 339 , 340 , 456 , 457 , 458 , 464 , 467 , 473 , 474 , 486 , 487 , 488 , 489 , 524 , 527 , 533 , 535 , 537 , 539 , 544 , 592 , 607 , 608 , 609 , 614 , 616 , 628 , 649 , 650 , 651 , 652 , 690 , 691 , 692 , 693 , 697 , 731 , 732 , 733 , 734 , 735 , 773 , 775 , 783 , 784 , 785 , 786 , 796 , 797 , 798 , 810 , 811 , 812 , 813 , 814 , 815 , 816 , 817 , 818 , 819 , 820 , 821 , 822 , 823 , 824 , 825 , 826 , 827 , 828 , 829 , 830 , 831 , 832 , 833 , 834 , 835 , 839 , 850 , 851 , 852 , 853 , 862 , 863 , 867 , 869 , 871 , 872 , 873 , 874 , 882 , 883 , 884 , 885 , 896 , 897 , 909 , 914 , 919 , 920 , 922 , 926 , 927 , 928 , 929 , 930 , 931 , 932 , 933 , 934 , 954 ) , non-small cell lung cancer ( 12 , 16 , 29 , 30 , 31 , 33 , 34 , 36 , 45 , 49 , 50 , 51 , 52 , 53 , 83 , 84 , 85 , 86 , 89 , 90 , 91 , 92 , 98 , 99 , 100 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 113 , 184 , 185 , 186 , 187 , 189 , 262 , 264 , 266 , 268 , 278 , 323 , 324 , 326 , 327 , 328 , 456 , 457 , 458 , 464 , 467 , 473 , 474 , 486 , 487 , 488 , 489 , 524 , 527 , 537 , 544 , 592 , 607 , 614 , 616 , 649 , 650 , 651 , 652 , 690 , 691 , 692 , 693 , 697 , 731 , 732 , 733 , 734 , 735 , 773 , 775 , 783 , 784 , 785 , 786 , 796 , 797 , 798 , 810 , 811 , 812 , 813 , 814 , 815 , 816 , 817 , 818 , 819 , 820 , 821 , 823 , 824 , 825 , 826 , 827 , 829 , 830 , 831 , 832 , 833 , 834 , 835 , 850 , 851 , 852 , 853 , 869 , 871 , 872 , 873 , 874 , 885 , 897 , 919 , 920 , 922 , 926 , 927 , 928 , 931 , 932 , 933 , 954 ) , non-small cell lung cancer, surrounding tissue ( 188 , 261 , 263 , 265 , 267 , 446 , 463 , 466 , 545 , 546 , 600 , 613 , 615 ) , non-small cell lung adenocarcinoma ( 12 , 16 , 29 , 30 , 31 , 32 , 33 , 34 , 36 , 83 , 84 , 85 , 86 , 89 , 90 , 91 , 92 , 98 , 99 , 100 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 113 , 200 , 278 , 323 , 324 , 326 , 327 , 486 , 487 , 488 , 489 , 524 , 544 , 607 , 649 , 650 , 651 , 652 , 783 , 784 , 797 , 798 , 867 , 919 ) , non-small cell lung adenocarcinoma, surrounding tissue ( 112 , 538 , 547 ) , non-small cell large cell lung carcinoma ( 30 , 33 ) , non-small cell squamous cell lung carcinoma ( 32 , 101 , 200 , 329 , 331 , 332 , 334 , 335 , 336 , 338 , 339 , 340 , 608 , 609 , 783 , 784 ) , small-cell lung cancer ( 882 , 896 , 909 , 914 , 929 , 930 , 934 ) , lung cancer, surrounding tissue ( 127 , 128 , 129 , 130 , 155 , 157 , 173 , 175 , 177 , 178 , 468 , 531 , 532 , 534 ) , lymphoma ( 37 , 705 ) , Burkitt's lymphoma ( 37 ) , neuroblastoma ( 20 , 147 , 148 , 149 , 150 , 151 , 152 , 514 , 515 , 516 , 517 , 518 , 519 , 618 , 619 , 622 , 623 , 624 , 698 , 699 , 703 , 742 , 854 , 855 , 856 , 880 ) , ovarian cancer ( 132 , 142 , 143 , 144 , 145 , 146 , 159 , 160 , 172 , 190 , 197 , 198 , 199 , 743 , 745 , 746 , 747 , 748 , 749 , 755 , 756 , 757 , 758 , 759 , 760 , 903 ) , ovarian epithelial carcinoma ( 132 , 143 , 145 ) , pancreatic cancer ( 282 , 341 , 772 , 939 , 940 , 941 , 942 , 943 , 944 , 950 , 951 , 952 ) , pancreatic carcinoma ( 282 , 772 , 941 , 942 , 950 , 951 , 952 ) , pancreatic ductal adenocarcinoma ( 7 ) , pancreatic cancer, surrounding tissue ( 343 , 688 ) , multiple myeloma ( 447 ) , prostate cancer ( 7 , 15 , 19 , 337 , 777 , 945 , 955 ) , salivary gland cancer ( 499 , 500 , 501 , 502 , 503 , 504 , 505 , 506 , 507 , 508 , 509 ) , melanoma skin cancer ( 24 , 492 , 493 , 494 , 495 , 496 , 521 , 522 , 621 ) , non-melanoma skin cancer ( 947 , 948 , 949 ) , teratoma ( 183 ) , teratoma, surrounding tissue ( 631 ) , testicular cancer ( 510 ) , thymic carcinoma ( 118 , 119 , 120 , 121 ) , thyroid cancer ( 674 , 864 ) , follicular thyroid carcinoma ( 864 ) , thyroid cancer, surrounding tissue ( 632 ) , ventricular tachycardia ( 122 , 123 , 124 , 133 ) , hypersplenism ( 704 )
Relevant cell line - cell type - tissue:
'fat, white' ( 46 ) , 'liver, para-cholangiocellular carcinoma tissue' ( 140 ) , 143B (bone cell) ( 741 ) , 184A1 (epithelial) ( 317 ) , 23132/87 (gastric) [RAIG1 (human), knockdown] ( 54 , 55 ) , 23132/87 (gastric) ( 56 , 876 ) , 293 (epithelial) [AT1 (human), transfection] ( 154 ) , 293 (epithelial) ( 8 , 9 , 10 , 153 , 162 , 536 , 648 , 675 , 964 , 969 , 970 , 973 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 963 , 964 ) , 3T3 (fibroblast) ( 9 , 41 , 912 ) , 5637 (bladder cell) ( 843 ) , A431 (epithelial) ( 28 , 947 , 948 , 949 ) , A498 (renal) ( 163 ) , A549 (pulmonary) [LKB1 (human), no information] ( 651 ) , A549 (pulmonary) [SRXN1 (human), transfection] ( 628 ) , A549 (pulmonary) ( 29 , 38 , 71 , 323 , 324 , 649 , 650 , 822 , 926 ) , ACC-S (adenoidal) ( 548 , 550 ) , AGS (gastric) ( 77 , 879 ) , AU565 (breast cell) ( 117 ) , BAEC (endothelial) ( 968 ) , BEAS-2B (epithelial) [LKB1 (human), no information] ( 477 , 478 ) , BEAS-2B (epithelial) ( 475 , 476 ) , bladder ( 230 , 237 , 238 , 239 , 240 , 241 ) , bone marrow ( 791 , 795 , 801 , 802 , 803 , 804 , 806 ) , brain ( 878 ) , breast ( 224 , 225 , 226 , 227 , 231 , 232 , 233 , 234 , 235 , 236 , 667 , 668 , 669 , 670 , 671 , 672 , 673 , 676 , 677 , 689 , 728 , 729 , 771 , 774 , 844 , 848 ) , BT-20 (breast cell) ( 40 ) , BT-474 (breast cell) ( 117 , 345 ) , BV-173 (myeloid) ( 325 ) , BxPC-3 (pancreatic) ( 939 , 940 , 943 , 944 ) , Caco-2 (intestinal) ( 648 , 761 ) , Cal-12T (pulmonary) ( 36 ) , CAL-148 (breast cell) ( 857 ) , CAL-29 (bladder cell) ( 842 ) , Calu 6 (pulmonary) ( 45 ) , Calu-3 (pulmonary) ( 31 , 926 ) , CHO (fibroblast) ( 965 ) , cholangiocyte-liver ( 292 , 304 , 316 , 469 , 470 , 638 ) , CLL23LB4 (B lymphocyte) ( 936 ) , CMK (megakaryoblast) ( 890 , 891 , 892 , 937 ) , COLO-680N (esophageal) [RAIG1 (human), knockdown] ( 57 ) , colon ( 448 , 450 , 451 , 452 , 453 , 454 , 459 , 460 , 461 , 462 , 485 , 590 , 610 , 644 , 645 , 646 , 647 , 653 , 654 , 656 , 657 , 761 , 765 ) , COS (fibroblast) ( 912 , 958 , 972 , 974 ) , COS7 (fibroblast) ( 39 ) , CTV-1 (myeloid) ( 938 ) , Daoy ( 72 ) , DBTRG-05MG (glial) ( 900 ) , DLD1 (intestinal) ( 11 , 761 ) , DMS153 (pulmonary) ( 34 , 893 , 894 , 895 , 929 ) , DMS53 (pulmonary) ( 909 ) , DU 145 (prostate cell) ( 19 ) , DU4475 (breast cell) ( 849 ) , DV-90 (pulmonary) ( 863 ) , EC (endothelial) ( 510 ) , ECV304 (endothelial) ( 962 ) , endothelial ( 959 ) , epithelial-lens ( 73 ) , esophagus ( 352 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 371 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 420 , 421 , 422 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 , 436 , 437 , 438 , 439 , 440 , 441 , 443 , 444 ) , EVSA-T (breast cell) ( 870 ) , Focus (hepatic) ( 23 ) , G-292 (bone cell) ( 766 ) , germ cell-teratoma ( 631 ) , GRANTA-519 (B lymphocyte) ( 705 ) , HaCaT (keratinocyte) ( 648 ) , HAEC (endothelial) ( 946 ) , HBE (epithelial) ( 926 ) , HCC15 (pulmonary) ( 32 ) , HCC1599 (breast cell) ( 837 ) , HCC366 (pulmonary) ( 45 ) , HCC44 (pulmonary) ( 36 ) , HCC78 (pulmonary) ( 33 , 45 , 85 , 86 , 91 , 92 , 524 ) , HCC827 (pulmonary) ( 16 , 31 , 326 , 797 , 798 , 919 ) , HCT116 (intestinal) ( 3 , 47 , 67 , 68 , 69 , 87 , 88 , 93 , 94 , 648 , 761 , 916 , 917 ) , heart ( 122 , 123 , 124 , 133 , 683 , 684 , 685 , 686 , 687 ) , HEK293T (epithelial) ( 7 , 44 ) , HeLa (cervical) ( 141 , 164 , 194 , 195 , 620 , 967 ) , Hep 3B2.1-7 (hepatic) ( 529 ) , hepatic-'liver, para-cholangiocellular carcinoma tissue' ( 302 , 484 , 642 , 716 ) , hepatic-'liver, para-hepatocellular carcinoma tissue' ( 285 , 287 , 301 , 303 , 307 , 310 , 314 , 471 , 634 ) , hepatocyte-liver ( 284 , 286 , 288 , 291 , 293 , 294 , 295 , 298 , 299 , 300 , 305 , 306 , 308 , 312 , 315 , 318 , 633 , 636 , 637 , 717 ) , HepG2 (hepatic) ( 322 ) , hLECs (epithelial) ( 24 ) , HLF (hepatic) ( 321 ) , HMVEC (endothelial) ( 881 ) , HOS (bone cell) ( 740 ) , HPAEC (endothelial) ( 43 ) , Hs746T (pancreatic) ( 845 ) , Hs766T (pancreatic) ( 942 ) , HT-29 (intestinal) ( 19 , 648 , 761 , 904 , 953 ) , Huh28 (hepatic) ( 528 ) , Huh7 (hepatic) ( 612 ) , HUVEC (endothelial) ( 22 , 158 , 536 , 552 , 553 , 554 , 555 , 556 , 557 , 558 , 559 , 910 , 911 ) , IB4 (B lymphocyte) ( 37 ) , IM95 (gastric) ( 708 ) , JHH-2 (hepatic) ( 530 ) , JHH-6 (hepatic) ( 525 ) , Jiyoye (B lymphocyte) ( 37 ) , Jurkat (T lymphocyte) ( 60 , 61 , 62 , 63 , 64 , 65 , 66 , 78 , 79 , 80 , 82 , 97 , 114 , 115 , 116 , 125 , 126 , 165 , 180 , 181 , 215 , 216 , 217 , 218 , 220 , 221 , 222 , 223 , 247 , 248 , 249 , 253 , 254 , 255 , 256 , 257 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 283 , 289 , 290 , 319 , 330 , 333 , 347 , 348 , 349 , 465 , 481 , 482 , 483 , 520 , 523 , 591 , 617 , 625 , 626 , 627 , 629 , 630 , 635 , 639 , 640 , 641 , 643 , 655 , 723 , 724 , 725 , 726 , 727 , 736 , 737 , 738 , 744 , 750 , 778 , 779 , 780 , 789 , 800 , 836 , 923 , 924 , 925 , 964 ) , K562 (erythroid) ( 70 , 134 , 135 , 136 , 137 , 138 , 139 , 179 , 192 , 196 , 219 , 228 , 229 , 250 , 251 , 252 , 342 , 344 , 490 , 491 , 665 , 682 , 769 , 787 , 788 , 790 , 805 , 807 , 808 , 809 , 901 ) , Kasumi-1 (myeloid) ( 886 ) , KATO III (gastric) ( 877 ) , KELLY (neural crest) ( 20 , 880 ) , kidney ( 243 , 258 , 259 , 260 , 279 , 280 , 281 ) , KPL-4 (breast cell) ( 35 ) , Kyse180 (esophageal) ( 171 ) , Kyse520 (esophageal) ( 860 ) , Kyse70 (esophageal) ( 858 , 859 , 861 ) , L929 (fibroblast) ( 905 ) , LAN-6 (neural crest) ( 20 , 514 , 515 , 516 , 517 , 518 , 519 , 618 , 619 ) , LAPC-4 (prostate cell) ( 7 ) , larynx ( 666 , 751 , 752 , 753 , 754 , 770 , 776 ) , liver ( 26 , 140 , 242 , 244 , 245 , 246 , 296 , 297 , 309 , 311 , 313 , 472 ) , LN18 (glial) ( 899 ) , LNCaP (prostate cell) ( 15 , 337 , 955 , 966 ) , LOU-NH91 (squamous) ( 32 ) , Ls174T (intestinal) ( 761 ) , lung ( 29 , 30 , 31 , 32 , 33 , 34 , 36 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 127 , 128 , 129 , 130 , 131 , 155 , 156 , 157 , 173 , 174 , 175 , 176 , 177 , 178 , 184 , 185 , 186 , 187 , 188 , 189 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 329 , 331 , 332 , 334 , 335 , 336 , 338 , 339 , 340 , 446 , 456 , 457 , 458 , 463 , 464 , 466 , 467 , 468 , 486 , 487 , 488 , 489 , 531 , 532 , 533 , 534 , 535 , 537 , 538 , 539 , 544 , 545 , 546 , 547 , 592 , 600 , 607 , 608 , 609 , 613 , 614 , 615 , 616 , 690 , 691 , 692 , 693 , 697 , 731 , 732 , 733 , 734 , 735 , 773 , 775 , 810 , 811 , 812 , 813 , 814 , 815 , 816 , 817 , 818 , 819 , 820 , 821 , 823 , 824 , 825 , 826 , 827 , 828 , 829 , 830 , 831 , 832 , 833 , 834 , 835 , 839 , 850 , 851 , 852 , 853 , 874 , 883 , 884 , 885 , 913 , 914 , 918 ) , LXF-289 (pulmonary) ( 871 ) , M059J (glial) ( 898 ) , MCF-10A (breast cell) ( 906 ) , MCF-7 (breast cell) [HER2 (human), transfection] ( 908 ) , MCF-7 (breast cell) ( 4 , 9 , 14 , 162 , 648 , 957 , 963 ) , MCF-7E ( 7 ) , MCF10A1 (epithelial) [HER2 (human), transfection] ( 908 ) , MDA-MB-231 (breast cell) ( 13 , 14 , 18 , 24 , 648 ) , MDA-MB-361 (breast cell) ( 346 ) , MDA-MB-468 (breast cell) ( 117 , 956 , 961 ) , MDCK (epithelial) ( 926 ) , MEF (fibroblast) [PTP1B (mouse)] ( 889 ) , MEF (fibroblast) ( 703 , 960 ) , MG63 (bone cell) ( 739 ) , MHH-NB-11 (neural crest) ( 20 , 854 ) , MIA PaCa-2 (pancreatic) ( 950 , 951 , 952 ) , MKN-45 (gastric) ( 74 , 75 , 76 , 95 , 96 , 166 , 167 , 168 , 169 , 191 , 193 , 200 , 455 , 541 , 542 , 543 , 730 , 781 , 782 , 799 ) , MKN-7 (gastric) ( 720 ) , MKN-74 (gastric) ( 721 ) , ML-1 [Human leukemia] (myeloid) ( 864 ) , MO1043 (B lymphocyte) ( 921 ) , monocyte ( 768 , 915 ) , MV4-11 (macrophage) ( 320 , 442 , 445 , 794 ) , myocyte-heart ( 973 ) , NCCIT (epithelial) ( 183 ) , NCI-H1299 (pulmonary) ( 30 ) , NCI-H1355 (pulmonary) ( 29 , 862 ) , NCI-H1373 (pulmonary) ( 954 ) , NCI-H1437 (pulmonary) ( 34 , 36 , 926 ) , NCI-H1648 (pulmonary) ( 45 ) , NCI-H1650 (pulmonary) ( 31 , 49 , 50 , 51 , 52 , 53 , 922 , 931 ) , NCI-H1666 (pulmonary) ( 36 , 933 ) , NCI-H1703 (squamous) ( 32 , 200 , 350 , 351 , 526 , 527 , 783 , 784 ) , NCI-H1734 (pulmonary) ( 30 ) , NCI-H1781 (pulmonary) ( 33 ) , NCI-H1792 (pulmonary) [LKB1 (human), no information] ( 473 , 474 ) , NCI-H1792 (pulmonary) ( 29 , 479 , 480 , 926 ) , NCI-H1944 (pulmonary) ( 30 ) , NCI-H1975 (pulmonary) ( 12 , 31 , 327 , 927 , 928 , 932 ) , NCI-H2030 (pulmonary) ( 897 ) , NCI-H2073 (pulmonary) ( 32 , 34 , 873 ) , NCI-H209 (pulmonary) ( 34 , 882 ) , NCI-H2106 (pulmonary) ( 31 ) , NCI-H2126 (pulmonary) ( 652 ) , NCI-H2228 (pulmonary) ( 33 ) , NCI-H2286 (pulmonary) ( 896 ) , NCI-H23 (pulmonary) ( 29 ) , NCI-H2342 (pulmonary) ( 32 , 872 ) , NCI-H2347 (pulmonary) ( 920 ) , NCI-H2405 (pulmonary) ( 36 ) , NCI-H2452 (pulmonary) ( 869 ) , NCI-H292 (pulmonary) ( 170 ) , NCI-H3122 (pulmonary) ( 33 , 83 , 84 , 89 , 90 ) , NCI-H3255 (pulmonary) ( 200 , 328 , 540 , 785 , 786 , 796 ) , NCI-H358 (pulmonary) ( 30 ) , NCI-H441 (pulmonary) ( 29 , 278 ) , NCI-H460 (pulmonary) ( 30 , 926 ) , NCI-H522 (pulmonary) ( 926 ) , NCI-H661 (pulmonary) ( 33 ) , NCI-H69 (pulmonary) ( 930 , 934 ) , NCI-H838 (pulmonary) ( 34 ) , NCI-H929 (B lymphocyte) ( 447 ) , neutrophil ( 915 ) , NOMO-1 (myeloid) ( 792 , 793 , 865 ) , NT2 (testicular) ( 182 , 510 ) , NUGC-2 (gastric) ( 718 ) , NUGC-3 (gastric) ( 709 ) , NUGC-4 (gastric) ( 719 ) , OCI/AML3 (myeloid) ( 902 ) , OCUM-1 (gastric) ( 706 ) , ovary ( 159 , 160 , 172 , 190 , 197 , 198 , 199 , 743 , 745 , 746 , 747 , 748 , 749 , 755 , 756 , 757 , 758 , 759 , 760 ) , OVKATE (ovarian) ( 142 , 144 ) , OVMANA (ovarian) ( 132 , 143 , 145 ) , OZ (bile-duct cell) [RAIG1 (human), knockdown] ( 58 , 59 ) , PANC-1 (pancreatic) ( 282 ) , pancreas ( 341 , 343 , 688 , 772 ) , PC3 (prostate cell) ( 7 , 777 , 945 ) , PC9 (pulmonary) ( 866 ) , PC9-TAR (pulmonary) ( 867 ) , PL-45 (pancreatic) ( 7 ) , placenta ( 888 ) , platelet-blood ( 25 , 153 , 971 , 975 ) , PNT1A (prostate cell) ( 7 ) , RERF-GC-1B (gastric) ( 707 ) , RMUG-S (ovarian) ( 146 ) , SACC-83 (salivary gland) ( 549 , 551 ) , salivary gland ( 499 , 500 , 501 , 502 , 503 , 504 , 505 , 506 , 507 , 508 , 509 , 511 , 512 , 513 ) , SCH (gastric) ( 722 ) , SF9 ( 11 ) , SH-SY5Y (neural crest) ( 20 , 147 , 148 , 977 ) , SK-ES-1 ( 767 ) , SK-LU-1 (pulmonary) ( 926 ) , SK-N-BE(2) (neural crest) ( 20 , 150 , 151 , 152 , 698 , 699 ) , SKBr3 (breast cell) ( 40 ) , skin ( 492 , 493 , 494 , 495 , 496 , 521 , 522 , 621 ) , SKNDZ (neural crest) ( 20 , 855 ) , SKNFI (neural crest) ( 20 , 856 ) , SKOV-3 (ovarian) ( 903 ) , SMS-KCN (neural crest) ( 20 , 622 , 623 , 624 , 742 ) , SMS-KCN-A (neural crest) ( 20 , 149 ) , SNU-1079 (hepatic) ( 498 ) , SNU-1196 (hepatic) ( 497 ) , SNU-16 (gastric) ( 875 ) , SNU-182 (hepatic) ( 611 ) , SNU-449 (hepatic) ( 449 ) , spleen ( 704 ) , stomach ( 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 560 , 561 , 562 , 563 , 564 , 565 , 566 , 567 , 568 , 569 , 570 , 571 , 572 , 573 , 574 , 575 , 576 , 577 , 578 , 579 , 580 , 581 , 582 , 583 , 584 , 585 , 586 , 587 , 588 , 589 , 593 , 594 , 595 , 596 , 597 , 598 , 599 , 601 , 602 , 603 , 604 , 605 , 606 , 678 , 679 , 680 , 681 , 694 , 695 , 696 , 700 , 701 , 702 , 710 , 711 , 712 , 713 , 714 , 715 ) , Su.86.86 (pancreatic) ( 941 ) , SUM159 (breast cell) ( 13 , 18 ) , SW48 (intestinal) ( 761 ) , SW480 (intestinal) ( 648 ) , SYF (fibroblast) ( 965 ) , T47D (breast cell) ( 648 ) , T84 (intestinal) ( 42 ) , thymus ( 118 , 119 , 120 , 121 ) , thyroid ( 632 , 674 ) , U2OS (bone cell) ( 14 ) , UACC-812 (breast cell) ( 838 ) , UT-7 (myeloid) ( 907 ) , YUSAC2 (melanocyte) ( 24 ) , Z-55 (myeloid) ( 887 )

Upstream Regulation
Regulatory protein:
CD63 (human) ( 675 ) , Chk1 (human) ( 3 , 11 ) , CSK (human) ( 15 ) , CTH (human) ( 141 ) , DOK2 (human) ( 912 ) , JAM-A (human) ( 25 ) , NEO1 (human) ( 510 ) , PAG (rat) ( 648 ) , PKCD (human) ( 40 ) , PPP1CA (human) ( 153 ) , PPP2CA (human) ( 153 ) , PTP1B (human) ( 40 ) , PTP4A1 (human) ( 822 ) , PTPN13 (human) ( 162 ) , PTPRA (human) ( 17 , 703 ) , PTPRJ (human) ( 28 , 536 ) , PTPRK (human) ( 908 ) , SGK223 (human) ( 77 ) , SHP-2 (human) ( 510 ) , SPARC (human) ( 72 ) , SRXN1 (human) ( 628 )
Putative in vivo kinases:
CSK (human) ( 25 , 964 ) , Src (rat) ( 973 )
Kinases, in vitro:
Chk1 (human) ( 11 ) , CSK (human) ( 3 , 11 , 868 ) , Src (human) ( 973 , 976 )
Putative upstream phosphatases:
PPP2CA (human) ( 40 ) , PTP1B (human) ( 153 , 761 , 905 ) , PTPRA (human) ( 972 ) , PTPRJ (human) ( 28 , 44 ) , SHP-2 (human) ( 18 )
Phosphatases, in vitro:
PTEN (human) ( 117 ) , SHP-2 (human) ( 959 )
Treatments:
afatinib ( 12 ) , androgen_withdrawal ( 15 ) , antithromb ( 915 ) , aripiprazole ( 10 ) , bacterial infection ( 42 ) , bradykinin ( 962 ) , BSA ( 25 ) , Ca(2+) ( 43 ) , catalase ( 21 ) , CinnGEL_2-methylester ( 761 ) , colforsin ( 964 ) , cytochalasin_D ( 971 ) , D-t-EtDO-P4 ( 962 ) , dasatinib ( 4 ) , EGF ( 40 , 912 , 956 , 958 , 965 , 966 ) , ephrin_A1 ( 777 ) , Escherichia_coli_lysate ( 42 ) , ethanol ( 768 ) , fibrinogen ( 25 , 971 ) , fibronectin ( 822 , 905 ) , gefitinib ( 16 ) , glabridin ( 71 ) , glutathione ( 21 ) , H-89 ( 964 ) , H2O2 ( 22 , 27 , 158 , 960 ) , heregulin ( 963 ) , KT5720 ( 964 ) , LPS ( 768 ) , MMS ( 8 ) , MSI-1436 ( 141 ) , netrin-1 ( 510 ) , nocodazole ( 164 ) , okadaic_acid ( 153 ) , phorbol_ester ( 977 ) , PP2 ( 888 , 958 , 962 ) , PP3 ( 888 ) , prostaglandin_E ( 964 ) , PTP1B_inhibitor_compound_II ( 905 ) , PTPI_IV ( 27 ) , serum ( 888 ) , serum_starvation ( 843 ) , SII_angiotensin_2 ( 154 ) , siRNA ( 27 , 40 , 536 , 822 , 908 ) , TGF-beta ( 21 , 908 ) , thrombin ( 975 ) , TIMP2 ( 881 ) , TT-232 ( 972 ) , tunicamycin ( 141 ) , vanadate ( 21 , 881 ) , VEGF ( 536 , 968 )

Downstream Regulation
Effects of modification on Src:
activity, induced ( 41 ) , enzymatic activity, induced ( 25 , 40 ) , enzymatic activity, inhibited ( 4 , 73 , 77 , 153 , 628 , 868 , 958 , 970 , 974 ) , intracellular localization ( 4 ) , molecular association, regulation ( 7 , 868 , 973 ) , phosphorylation ( 28 , 39 , 117 ) , protein conformation ( 868 ) , protein degradation ( 73 ) , protein processing ( 973 )
Effects of modification on biological processes:
cell adhesion, inhibited ( 28 ) , cell growth, induced ( 40 ) , cell motility, inhibited ( 18 )
Induce interaction with:
Src (human) ( 868 , 973 )
Inhibit interaction with:
FBXL7 (human) ( 7 )

Disease / Diagnostics Relevance
Relevant diseases:
colorectal carcinoma ( 761 ) , cholangiocellular carcinoma ( 140 )

References 

1

Chu CT, Chen YH, Chiu WT, Chen HC (2021) Tyrosine phosphorylation of lamin A by Src promotes disassembly of nuclear lamina in interphase. Life Sci Alliance 4
34385357   Curated Info

2

Tognoli ML, et al. (2021) RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis. EMBO J, e107680
34532864   Curated Info

3

Chüeh AC, et al. (2021) CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation. Oncogene
33767439   Curated Info

4

Higuchi M, et al. (2021) Paradoxical activation of c-Src as a drug-resistant mechanism. Cell Rep 34, 108876
33761359   Curated Info

5

Toral KJ, Wuenschel MA, Black EP (2021) Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors. PLoS One 16, e0256416
34437586   Curated Info

6

Song HE, et al. (2021) N-terminus-independent activation of c-Src via binding to a tetraspan(in) TM4SF5 in hepatocellular carcinoma is abolished by the TM4SF5 C-terminal peptide application. Theranostics 11, 8092-8111
34335982   Curated Info

7

Moro L, et al. (2020) Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. Nat Cell Biol
32839549   Curated Info

8

Ci S, et al. (2020) Src-mediated phosphorylation of GAPDH regulates its nuclear localization and cellular response to DNA damage. FASEB J
32539222   Curated Info

9

Huang C, et al. (2018) Acetylation within the N- and C-terminal domains of Src regulate distinct roles of STAT3-mediated tumorigenesis. Cancer Res
29531159   Curated Info

10

Kim MS, et al. (2018) Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget 9, 5979-5992
29464048   Curated Info

11

Advani G, et al. (2017) Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine. Cell Commun Signal 15, 29
28784162   Curated Info

12

Booth L, et al. (2016) The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget 7, 19620-30
26934000   Curated Info

13

Park JH, et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14, 2154-65
26923594   Curated Info

14

Vlahov N, et al. (2015) Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion. Curr Biol 25, 3019-34
26549256   Curated Info

15

Yang CC, et al. (2015) Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass. Oncotarget 6, 22060-71
26091350   Curated Info

16

Phuchareon J, McCormick F, Eisele DW, Tetsu O (2015) EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A 112, E3855-63
26150526   Curated Info

17

Fang XQ, et al. (2015) Focal adhesion kinase regulates the phosphorylation protein tyrosine phosphatase-α at Tyr789 in breast cancer cells. Mol Med Rep 11, 4303-8
25625869   Curated Info

18

Sausgruber N, et al. (2015) Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases. Oncogene 34, 2272-8
24931162   Curated Info

19

Liu W, et al. (2015) The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget 6, 8851-74
25860930   Curated Info

20

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

21

Zhang H, Davies KJ, Forman HJ (2015) TGFβ1 rapidly activates Src through a non-canonical redox signaling mechanism. Arch Biochem Biophys 568, 1-7
25585026   Curated Info

22

Jeon BK, Kwon K, Kang JL, Choi YH (2015) Csk-Induced Phosphorylation of Src at Tyrosine 530 is Essential for H2O2-Mediated Suppression of ERK1/2 in Human Umbilical Vein Endothelial Cells. Sci Rep 5, 12725
26234813   Curated Info

23

Gujral TS, et al. (2014) A noncanonical frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell 159, 844-56
25417160   Curated Info

24

Ghaffari A, et al. (2014) A novel role for ezrin in breast cancer angio/lymphangiogenesis. Breast Cancer Res 16, 438
25231728   Curated Info

25

Naik MU, Caplan JL, Naik UP (2014) Junctional adhesion molecule-A suppresses platelet integrin αIIbβ3 signaling by recruiting Csk to the integrin-c-Src complex. Blood 123, 1393-402
24300854   Curated Info

26

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

27

Jo A, et al. (2014) SHP-2 Binds to Caveolin-1 and Regulates Src Activity via Competitive Inhibition of CSK in Response to H2O2 in Astrocytes. PLoS One 9, e91582
24632723   Curated Info

28

Takahashi K, et al. (2014) CD148 Tyrosine Phosphatase Promotes Cadherin Cell Adhesion. PLoS One 9, e112753
25386896   Curated Info

29

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

30

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

31

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

32

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

33

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

34

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

35

Tzouros M, et al. (2013) Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics. Mol Cell Proteomics 12, 3339-49
23882028   Curated Info

36

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

37

Wang L, Ning S (2013) Interferon Regulatory Factor 4 Is Activated through c-Src-Mediated Tyrosine Phosphorylation in Virus-Transformed Cells. J Virol 87, 9672-9
23804646   Curated Info

38

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

39

Burgo A, et al. (2013) Increased activity of the Vesicular Soluble N-Ethylmaleimide-sensitive Factor Attachment Protein Receptor TI-VAMP/VAMP7 by Tyrosine Phosphorylation in the Longin Domain. J Biol Chem 288, 11960-72
23471971   Curated Info

40

Wang J, Yu L, Zheng X (2013) PTPα-mediated Src activation by EGF in human breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 45, 320-9
23532252   Curated Info

41

Morgan MR, et al. (2013) Syndecan-4 phosphorylation is a control point for integrin recycling. Dev Cell 24, 472-85
23453597   Curated Info

42

In J, et al. (2013) Serine Protease EspP from Enterohemorrhagic Escherichia Coli Is Sufficient to Induce Shiga Toxin Macropinocytosis in Intestinal Epithelium. PLoS One 8, e69196
23874912   Curated Info

43

Komarova YA, et al. (2012) VE-Cadherin Signaling Induces EB3 Phosphorylation to Suppress Microtubule Growth and Assemble Adherens Junctions. Mol Cell 48, 914-25
23159740   Curated Info

44

Spring K, et al. (2012) Tyrosine phosphorylation of DEP-1/CD148 as a mechanism controlling Src kinase activation, endothelial cell permeability, invasion, and capillary formation. Blood 120, 2745-56
22898603   Curated Info

45

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

46

Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11
22461510   Curated Info

47

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

48

Rikova K (2012) CST Curation Set: 14270; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 1mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

49

Possemato A (2012) CST Curation Set: 14060; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

50

Possemato A (2012) CST Curation Set: 14061; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

51

Possemato A (2012) CST Curation Set: 14062; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

52

Possemato A (2012) CST Curation Set: 14063; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

53

Possemato A (2012) CST Curation Set: 14058; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

54

Tucker M (2012) CST Curation Set: 13492; Year: 2012; Biosample/Treatment: cell line, 23132/87[RAIG1(knockdown)]/GPRC5A knockdown; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

55

Tucker M (2012) CST Curation Set: 13493; Year: 2012; Biosample/Treatment: cell line, 23132/87[RAIG1(knockdown)]/GPRC5A knockdown; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

56

Tucker M (2012) CST Curation Set: 13494; Year: 2012; Biosample/Treatment: cell line, 23132/87/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

57

Tucker M (2012) CST Curation Set: 13496; Year: 2012; Biosample/Treatment: cell line, Colo-680N[RAIG1(knockdown)]/GPRC5A knockdown; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

58

Tucker M (2012) CST Curation Set: 13501; Year: 2012; Biosample/Treatment: cell line, OZ[RAIG1(knockdown)]/GPRC5A knockdown; Disease: bile-duct cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

59

Tucker M (2012) CST Curation Set: 13502; Year: 2012; Biosample/Treatment: cell line, OZ[RAIG1(knockdown)]/GPRC5A knockdown; Disease: bile-duct cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

60

Zhou J (2012) CST Curation Set: 12609; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

61

Zhou J (2012) CST Curation Set: 12610; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

62

Zhou J (2012) CST Curation Set: 12611; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

63

Zhou J (2012) CST Curation Set: 12612; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

64

Mulhern D (2012) CST Curation Set: 13338; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

65

Mulhern D (2012) CST Curation Set: 13335; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

66

Mulhern D (2012) CST Curation Set: 13336; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

67

Mulhern D (2012) CST Curation Set: 13331; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

68

Mulhern D (2012) CST Curation Set: 13332; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

69

Mulhern D (2012) CST Curation Set: 13333; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

70

Mulhern D (2011) CST Curation Set: 13266; Year: 2011; Biosample/Treatment: cell line, K-562/untreated &'||' untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

71

Tsai YM, et al. (2011) Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/rho signaling pathway. Integr Cancer Ther 10, 341-9
21059620   Curated Info

72

Bhoopathi P, et al. (2011) SPARC mediates Src-induced disruption of actin cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42. Cell Signal 23, 1978-87
21798346   Curated Info

73

Pan Q, et al. (2011) Cdk5 targets active Src for ubiquitin-dependent degradation by phosphorylating Src(S75). Cell Mol Life Sci 68, 3425-36
21442427   Curated Info

74

Mulhern D (2011) CST Curation Set: 12645; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

75

Mulhern D (2011) CST Curation Set: 12853; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

76

Mulhern D (2011) CST Curation Set: 12854; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

77

Safari F, Murata-Kamiya N, Saito Y, Hatakeyama M (2011) Mammalian Pragmin regulates Src family kinases via the Glu-Pro-Ile-Tyr-Ala (EPIYA) motif that is exploited by bacterial effectors. Proc Natl Acad Sci U S A 108, 14938-43
21873224   Curated Info

78

Zhou J (2011) CST Curation Set: 12495; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

79

Zhou J (2011) CST Curation Set: 12496; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

80

Zhou J (2011) CST Curation Set: 12497; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

81

Oneyama C, et al. (2011) MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 30, 3489-501
21383697   Curated Info

82

Moritz A (2011) CST Curation Set: 12258; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

83

Possemato A (2011) CST Curation Set: 11907; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

84

Possemato A (2011) CST Curation Set: 11908; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

85

Possemato A (2011) CST Curation Set: 11909; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

86

Possemato A (2011) CST Curation Set: 11910; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

87

Possemato A (2011) CST Curation Set: 11911; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

88

Possemato A (2011) CST Curation Set: 11912; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

89

Possemato A (2011) CST Curation Set: 11919; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

90

Possemato A (2011) CST Curation Set: 11920; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

91

Possemato A (2011) CST Curation Set: 11921; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

92

Possemato A (2011) CST Curation Set: 11922; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

93

Possemato A (2011) CST Curation Set: 11923; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

94

Possemato A (2011) CST Curation Set: 11924; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

95

Possemato A (2011) CST Curation Set: 11925; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

96

Possemato A (2011) CST Curation Set: 11926; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

97

Guo A (2011) CST Curation Set: 11646; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

98

Ren H (2011) CST Curation Set: 11772; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

99

Ren H (2011) CST Curation Set: 11773; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

100

Ren H (2011) CST Curation Set: 11775; Year: 2011; Biosample/Treatment: cell line, RP92/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

101

Ren H (2011) CST Curation Set: 11776; Year: 2011; Biosample/Treatment: cell line, RP93/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

102

Ren H (2011) CST Curation Set: 11777; Year: 2011; Biosample/Treatment: cell line, RP94/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

103

Ren H (2011) CST Curation Set: 11778; Year: 2011; Biosample/Treatment: cell line, RP95/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

104

Ren H (2011) CST Curation Set: 11779; Year: 2011; Biosample/Treatment: cell line, RP96/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

105

Ren H (2011) CST Curation Set: 11780; Year: 2011; Biosample/Treatment: cell line, RP97/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

106

Ren H (2011) CST Curation Set: 11781; Year: 2011; Biosample/Treatment: cell line, RP98/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

107

Ren H (2011) CST Curation Set: 11783; Year: 2011; Biosample/Treatment: cell line, RP100/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

108

Ren H (2011) CST Curation Set: 11784; Year: 2011; Biosample/Treatment: cell line, RP101/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

109

Ren H (2011) CST Curation Set: 11785; Year: 2011; Biosample/Treatment: cell line, RP102/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

110

Ren H (2011) CST Curation Set: 11786; Year: 2011; Biosample/Treatment: cell line, RP103/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

111

Ren H (2011) CST Curation Set: 11787; Year: 2011; Biosample/Treatment: cell line, RP104/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

112

Ren H (2011) CST Curation Set: 11790; Year: 2011; Biosample/Treatment: cell line, FAC 13N/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

113

Ren H (2011) CST Curation Set: 11791; Year: 2011; Biosample/Treatment: cell line, FAC 13T/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

114

Possemato A (2011) CST Curation Set: 11711; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

115

Possemato A (2011) CST Curation Set: 11712; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

116

Possemato A (2011) CST Curation Set: 11713; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

117

Zhang S, et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17, 461-9
21399647   Curated Info

118

Li Y (2011) CST Curation Set: 10458; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

119

Li Y (2011) CST Curation Set: 10459; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

120

Li Y (2011) CST Curation Set: 10460; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

121

Li Y (2011) CST Curation Set: 10461; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

122

Li Y (2011) CST Curation Set: 10520; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

123

Li Y (2011) CST Curation Set: 10525; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

124

Li Y (2011) CST Curation Set: 10527; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

125

Possemato A (2011) CST Curation Set: 11629; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

126

Possemato A (2011) CST Curation Set: 11632; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

127

Tucker M (2011) CST Curation Set: 10943; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

128

Tucker M (2011) CST Curation Set: 10947; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

129

Tucker M (2011) CST Curation Set: 10949; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

130

Tucker M (2011) CST Curation Set: 10951; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

131

Tucker M (2011) CST Curation Set: 10952; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

132

Ren H (2011) CST Curation Set: 11303; Year: 2011; Biosample/Treatment: cell line, OVMANA/serum starved; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

133

Li Y (2011) CST Curation Set: 10456; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

134

Moritz A (2011) CST Curation Set: 11304; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

135

Moritz A (2011) CST Curation Set: 11305; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

136

Moritz A (2011) CST Curation Set: 11306; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

137

Moritz A (2011) CST Curation Set: 11307; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

138

Moritz A (2011) CST Curation Set: 11308; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

139

Moritz A (2011) CST Curation Set: 11309; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

140

Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640
21253578   Curated Info

141

Krishnan N, Fu C, Pappin DJ, Tonks NK (2011) H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response. Sci Signal 4, ra86
22169477   Curated Info

142

Ren H (2010) CST Curation Set: 10743; Year: 2010; Biosample/Treatment: cell line, OVKATE/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

143

Ren H (2010) CST Curation Set: 10744; Year: 2010; Biosample/Treatment: cell line, OVMANA/serum starved; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

144

Ren H (2010) CST Curation Set: 10740; Year: 2010; Biosample/Treatment: cell line, OVKATE/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

145

Ren H (2010) CST Curation Set: 10741; Year: 2010; Biosample/Treatment: cell line, OVMANA/serum starved; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

146

Ren H (2010) CST Curation Set: 10742; Year: 2010; Biosample/Treatment: cell line, RMUG-S/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

147

Guo A (2010) CST Curation Set: 10556; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

148

Guo A (2010) CST Curation Set: 10557; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/NGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

149

Guo A (2010) CST Curation Set: 10553; Year: 2010; Biosample/Treatment: cell line, SMS-KCN-A/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

150

Guo A (2010) CST Curation Set: 10551; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

151

Guo A (2010) CST Curation Set: 10549; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

152

Guo A (2010) CST Curation Set: 10548; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

153

Pradhan S, et al. (2010) Cross-talk between serine/threonine protein phosphatase 2A and protein tyrosine phosphatase 1B regulates Src activation and adhesion of integrin αIIbβ3 to fibrinogen. J Biol Chem 285, 29059-68
20615878   Curated Info

154

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

155

Tucker M (2010) CST Curation Set: 10316; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

156

Tucker M (2010) CST Curation Set: 10317; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

157

Tucker M (2010) CST Curation Set: 10314; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

158

Büchner N, et al. (2010) Downregulation of mitochondrial telomerase reverse transcriptase induced by H2O2 is Src kinase dependent. Exp Gerontol 45, 558-62
20211239   Curated Info

159

Ren H (2010) CST Curation Set: 10221; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411
Curated Info

160

Ren H (2010) CST Curation Set: 10180; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411
Curated Info

161

Rikova K (2010) CST Curation Set: 10032; Year: 2010; Biosample/Treatment: cell line, DFCI HCC827 triple/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

162

Glondu-Lassis M, et al. (2010) PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res 70, 5116-26
20501847   Curated Info

163

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

164

Vacaru AM, den Hertog J (2010) Serine Dephosphorylation of Receptor Protein Tyrosine Phosphatase {alpha} in Mitosis Induces Src Binding and Activation. Mol Cell Biol 30, 2850-61
20385765   Curated Info

165

Moritz A (2010) CST Curation Set: 9799; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

166

Moritz A (2010) CST Curation Set: 9788; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

167

Moritz A (2010) CST Curation Set: 9789; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

168

Moritz A (2010) CST Curation Set: 9787; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

169

Moritz A (2010) CST Curation Set: 9790; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

170

Li J, et al. (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6, 291-9
20190765   Curated Info

171

Tucker M (2010) CST Curation Set: 9227; Year: 2010; Biosample/Treatment: cell line, Kyse180/untreated; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

172

Ren H (2010) CST Curation Set: 8898; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

173

Hu Y (2010) CST Curation Set: 8711; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

174

Hu Y (2010) CST Curation Set: 8712; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

175

Hu Y (2010) CST Curation Set: 8707; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

176

Hu Y (2010) CST Curation Set: 8708; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

177

Hu Y (2010) CST Curation Set: 8713; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

178

Hu Y (2010) CST Curation Set: 8709; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

179

Moritz A (2010) CST Curation Set: 8835; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

180

Guo A (2010) CST Curation Set: 9182; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

181

Guo A (2010) CST Curation Set: 9181; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

182

Zhou J (2010) CST Curation Set: 9107; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

183

Zhou J (2010) CST Curation Set: 9106; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

184

Rikova K (2010) CST Curation Set: 9124; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

185

Rikova K (2010) CST Curation Set: 9127; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

186

Rikova K (2010) CST Curation Set: 9116; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

187

Rikova K (2010) CST Curation Set: 9122; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

188

Rikova K (2010) CST Curation Set: 9123; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

189

Rikova K (2010) CST Curation Set: 9125; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

190

Ren H (2010) CST Curation Set: 9096; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

191

Moritz A (2010) CST Curation Set: 9060; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

192

Moritz A (2010) CST Curation Set: 9049; Year: 2010; Biosample/Treatment: cell line, K562/untreated & calyculin_A; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

193

Moritz A (2010) CST Curation Set: 9061; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

194

Moritz A (2010) CST Curation Set: 9059; Year: 2010; Biosample/Treatment: cell line, HeLa/Peroxide; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

195

Moritz A (2010) CST Curation Set: 9058; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

196

Moritz A (2010) CST Curation Set: 9050; Year: 2010; Biosample/Treatment: cell line, K562/untreated & calyculin_A; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

197

Ren H (2010) CST Curation Set: 8896; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

198

Ren H (2010) CST Curation Set: 8893; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

199

Ren H (2010) CST Curation Set: 8822; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

200

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

201

Ren H (2009) CST Curation Set: 8029; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

202

Ren H (2009) CST Curation Set: 8022; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

203

Ren H (2009) CST Curation Set: 8028; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

204

Ren H (2009) CST Curation Set: 8025; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

205

Ren H (2009) CST Curation Set: 8023; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info